Eli Lilly to focus on selling COVID-19 antibody drug combination
Send a link to a friend
[April 12, 2021] (Reuters)
-Eli Lilly and Co said on Monday it had a
revised agreement with the U.S. government for its COVID-19 antibody
drug, bamlanivimab, which will now be sold in combination with another
therapy.
|
|
 Concerns over the impact on the drug's efficacy from rapidly
spreading coronavirus variants that are resistant to the drug when
administered alone led to the U.S. government stopping distribution
of the therapy last month.
Lilly and the U.S. government have agreed to modify their existing
agreement to enable the supply of etesevimab to complement doses of
bamlanivimab the U.S. government had already purchased, the
drugmaker said.
[to top of second column] |
 The earlier supply agreement
for bamlanivimab has been terminated and cancels
the remaining 350,856 doses of bamlanivimab that
were scheduled to be delivered by the end of
March 2021.
(Reporting by Manas Mishra in Bengaluru; Editing
by Shinjini Ganguli)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
